Evidence map›Paper›PMID 39748017›Full record

ArticleScientific reports2025

Predictive markers of rapid disease progression and chemotherapy resistance in triple-negative breast cancer patients following postoperative adjuvant therapy.

Tao Ma, Xiao-Meng Hao, Hong-Dan Chen, Min-Hui Zheng, Xiao-Geng Chen, Shuang-Long Cai, Jin Zhang

Abstract read
In one paragraph

Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Review
  6. Article
  7. Article
  8. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Tao Ma *The Third Department of Breast Cancer, Tianjin Medical University Cancer Institute & Hospital, National Clinical Research Center for Cancer, Tianjin, China.
Xiao-Meng Hao *The Third Department of Breast Cancer, Tianjin Medical University Cancer Institute & Hospital, National Clinical Research Center for Cancer, Tianjin, China.
Hong-Dan Chen *First Department of Cadre Clinic, Fujian Provincial Hospital, Shengli Clinical Medical College of Fujian Medical University, Fuzhou University Affiliated Provincial Hospital, Fuzhou, Fujian, China.
Min-Hui ZhengOral and Maxillofacial Surgery Thyroid and Hernia Surgery, Fujian Provincial Hospital, Shengli Clinical Medical College of Fujian Medical University, Fuzhou University Affiliated Provincial Hospital, Fuzhou, Fujian, China.
Xiao-Geng ChenDepartment of Breast Surgery, Fujian Provincial Hospital, Shengli Clinical Medical College of Fujian Medical University, Fuzhou University Affiliated Provincial Hospital, Fuzhou, Fujian, China.
Shuang-Long Cai *Department of Breast Surgery, Fujian Provincial Hospital, Shengli Clinical Medical College of Fujian Medical University, Fuzhou University Affiliated Provincial Hospital, Fuzhou, Fujian, China. caishuanglong16@163.com.
Jin Zhang *The Third Department of Breast Cancer, Tianjin Medical University Cancer Institute & Hospital, National Clinical Research Center for Cancer, Tianjin, China. zhangjinmuchtj@163.com.

Funding

Tianjin Key Medical Discipline(Specialty) Construction Project TJYXZDXK-009A
6 · The paper itself

Abstract

Triple-negative breast cancer (TNBC) is a diverse category with a subset that displays particularly aggressive characteristics, referred to in this study as "rapid relapse" TNBC (rrTNBC). This term is defined as the occurrence of distant metastasis or death within 24 months post-diagnosis. The paper mainly studies the clinicopathologic traits of TNBC patients experiencing rapid disease progression and chemotherapy resistance and identify predictive markers for this outcome. A retrospective evaluation was conducted on 2294 TNBC patients who underwent surgery at Tianjin Medical University Cancer Hospital. Of these, 369 were categorized as experiencing rapid relapse, while 1925 did not relapse rapidly. Logistic regression analysis was applied to determine potential markers predictive of rapid relapse post-chemotherapy. Both univariate and multivariate logistic regression analyses pinpointed several predictors of rapid relapse in TNBC patients post-chemotherapy. These include age at diagnosis (≥ 50 years, OR = 0.413, 95% CI: 0.289-0.590), postoperative pathological T staging (T2, OR = 2.557, 95% CI: 1.766-3.703; T3 + T4, OR = 3.725, 95% CI: 1.355-10.454), and N staging (N1, OR = 3.056, 95% CI: 2.021-4.619; N2, OR = 6.917, 95% CI: 3.920-12.206; N3, OR = 24.597, 95% CI: 11.875-50.948). Additionally, sTIL expression (intermediate, OR = 0.204, 95% CI: 0.139-0.300; high, OR = 0.020, 95% CI: 0.011-0.035) and Her2 expression (Her2 1+, OR = 0.470, 95% CI: 0.321-0.688) were identified as protective indicators against rapid relapse. A predictive model incorporating these predictors yielded a C-index of 0.898 in the training set and 0.938 in the validation set, with respective Brier scores of 0.079 and 0.073. The study successfully established and validated a predictive model for rapid disease progression and chemotherapy resistance in TNBC patients post-chemotherapy, demonstrating robust discrimination and accuracy.

Indexed as

Biomarkers, TumorDisease ProgressionDrug Resistance, NeoplasmTriple Negative Breast NeoplasmsAdultAgedChemotherapy, AdjuvantFemaleHumansMiddle AgedNeoplasm Recurrence, LocalNeoplasm StagingPrognosisRetrospective StudiesBiomarkers, TumorChemotherapy resistancePostoperative adjuvant therapyPredictive markersRapid disease progressionTriple-negative breast cancer

Identifiers

PMID39748017
PMCPMC11697311

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.